<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03446625</url>
  </required_header>
  <id_info>
    <org_study_id>1401-MAD-004-IO</org_study_id>
    <nct_id>NCT03446625</nct_id>
  </id_info>
  <brief_title>Resveratrol as a Preventive Treatment of OHSS</brief_title>
  <acronym>RES-OHSS</acronym>
  <official_title>Resveratrol as a Preventive Treatment of Ovarian Hyperstimulation Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IVI Madrid</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IVI Madrid</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of resveratrol treatment oh ovarian hyperstimulation syndrome in egg donors
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized clinical trial to evaluate the role of resveratrol in preventing ovarian
      hyperstimulation syndrome by reducing VGEF expression and estradiol production, imporving
      hemoconcentration and symptomathology of this condition
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 13, 2018</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum VEGF levels</measure>
    <time_frame>1 day</time_frame>
    <description>Serum determination of VEGF levels</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hemoconcentration</measure>
    <time_frame>1 day</time_frame>
    <description>Volume of red blood cells measured in percentage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum estradiol levels</measure>
    <time_frame>1 day</time_frame>
    <description>Serum determination of estradiol levels asessed in picograms per mililiter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ascitis</measure>
    <time_frame>1 day</time_frame>
    <description>Volume of liquid in Douglas pouch asessed in mililiters</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Resveratrol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Resveratrol will be administered orally at the dose of 2 g/day for 9 days, starting on the day of ovulation triggering.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo treatment will be administered for 9 days, starting on the day of ovulation triggering.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Resveratrol</intervention_name>
    <description>Resveratrol treatment (2 g/day) will be administered for 9 days, starting from oocyte maturation day.</description>
    <arm_group_label>Resveratrol</arm_group_label>
    <arm_group_label>Control</arm_group_label>
    <other_name>Resverasor Plus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo treatment (2 g/day) will be administered for 9 days, starting from oocyte maturation day.</description>
    <arm_group_label>Resveratrol</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Number of follicles greater than 12 mm after ovarian stimulation

          -  Number of retrieved oocytes greater than 21

        Exclusion Criteria:

          -  &gt;35 years-old

          -  PCOS

          -  Endometriosis

          -  Systemic pathology

          -  Positive serologies for HBV, HBC and HIV

          -  Abnormal karyotype
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Juan A Garc√≠a-Velasco, MD</last_name>
    <phone>911802900</phone>
    <email>Juan.Garcia.Velasco@ivi.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Israel Ortega, MD</last_name>
    <phone>911802900</phone>
    <email>Israel.Ortega@ivi.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ivi Madrid</name>
      <address>
        <city>Madrid</city>
        <zip>28023</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>IVI MADRID</last_name>
      <phone>91 180 29 00</phone>
      <email>israel.ortega@ivi.es</email>
    </contact>
    <investigator>
      <last_name>Israel Ortega, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Ortega I, Villanueva JA, Wong DH, Cress AB, Sokalska A, Stanley SD, Duleba AJ. Resveratrol reduces steroidogenesis in rat ovarian theca-interstitial cells: the role of inhibition of Akt/PKB signaling pathway. Endocrinology. 2012 Aug;153(8):4019-29. doi: 10.1210/en.2012-1385. Epub 2012 Jun 19.</citation>
    <PMID>22719052</PMID>
  </reference>
  <reference>
    <citation>Ortega I, Wong DH, Villanueva JA, Cress AB, Sokalska A, Stanley SD, Duleba AJ. Effects of resveratrol on growth and function of rat ovarian granulosa cells. Fertil Steril. 2012 Dec;98(6):1563-73. doi: 10.1016/j.fertnstert.2012.08.004. Epub 2012 Sep 6.</citation>
    <PMID>22959450</PMID>
  </reference>
  <reference>
    <citation>Basini G, Tringali C, Baioni L, Bussolati S, Spatafora C, Grasselli F. Biological effects on granulosa cells of hydroxylated and methylated resveratrol analogues. Mol Nutr Food Res. 2010 Jul;54 Suppl 2:S236-43. doi: 10.1002/mnfr.200900320.</citation>
    <PMID>20140899</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2017</study_first_submitted>
  <study_first_submitted_qc>February 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 27, 2018</study_first_posted>
  <last_update_submitted>March 23, 2018</last_update_submitted>
  <last_update_submitted_qc>March 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IVI Madrid</investigator_affiliation>
    <investigator_full_name>Juan A Garcia-Velasco</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>resveratrol</keyword>
  <keyword>OHSS</keyword>
  <keyword>PCOS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Ovarian Hyperstimulation Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Resveratrol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

